Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 15/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25274583 | 1.00 | HCAR3 (0.41) | HCAR3NAPRTMEN1KMT2AL3MBTL1 | |
| SCHEMBL25271979 | 0.81 | PIM1 (0.48) | HCAR3 | |
| SCHEMBL12013121 | 0.74 | CSNK2A2 (0.37) | — | |
| SCHEMBL609443 | 0.74 | HCAR3 (0.48) | HCAR3NAPRTHCAR2 | |
| SCHEMBL25234492 | 0.73 | PIK3C3 (0.35) | — | |
| SCHEMBL25232043 | 0.71 | IKBKB (0.43) | — | |
| SCHEMBL25227431 | 0.71 | CSNK2A2 (0.40) | — | |
| SCHEMBL25281879 | 0.70 | CSNK2A2 (0.36) | FASNTYK2 | |
| SCHEMBL3006651 | 0.69 | TNNI3K (0.40) | — | |
| SCHEMBL25276098 | 0.69 | TTK (0.44) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114222744-B | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFNα response | 百时美施贵宝公司 | 2024-06-25 | — | — | CN | disclosed |